Dendritic and lymphocytic cell infiltration in prostate carcinoma

Histology and Histopathology

Volumn 28, Issue 12, 2013, Pages 1621-1628

  Liu, Yishan ^a,c   Sæter, Thorstein ^b   Vlatkovic, Ljiljana ^a   Servoll, Einar ^b   Waaler, Gudmund ^b   Axcrona, Ulrika ^a   Giercksky, Karl Erik ^a,c   Nesland, Jahn M ^a,c   Suo, Zhen He ^a,c   Axcrona, Karol ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Sørlandet Sykehus HF ^*  (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

CD1a; Dendritic cells; Prostate cancer; T lymphocytes

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; DENDRITIC CELL; DISEASE FREE SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOSURVEILLANCE; KAPLAN MEIER METHOD; LYMPHOCYTE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGED; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOLOGIC SURVEILLANCE; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 84888119810     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Aalamian M., Pirtskhalaishvili G., Nunez A., Esche C., Shurin G.V., Huland E., Huland H. and Shurin M.R. (2001). Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46, 68-75.
2. Ananiev J., Gulubova M.V. and Manolova I.M. (2011). Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-ß 1 in human gastric cancer. Hepatogastroenterology 58, 1834-1840.
3. Bigotti G., Coli A. and Castagnola D. (1991). Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate 19, 73-87.
4. Bohling S.D. and Allison K.H. (2008). Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: A potential therapeutic target. Mod. Pathol. 21, 1527-1532.
5. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F. and Viola A. (2005). Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201, 1257-1568.
6. Coventry B. and Heinzel S. (2004). CD1a in human cancers: A new role for an old molecule. Trends. Immunol. 25, 242-248.
7. Coventry B.J. and Morton J. (2003). CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br. J. Cancer 89, 533-538.
8. Dadabayev A.R., Sandel M.H., Menon A.G., Morreau H., Melief C.J., Offringa R., van der Burg S.H., Janssen-van Rhijn C., Ensink N.G., Tollenaar R.A., van de Velde C.J. and Kuppen P.J. (2004). Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells. Cancer Immunol. Immunother. 53, 978-986.
9. Drake C.G. and Antonarakis E.S. (2012). Current status of immunological approaches for the treatment of prostate cancer. Curr. Opin. Urol. 22, 197-202.
10. Dunn G.P., Bruce A.T., Ikeda H., Old L.J. and Schreiber R.D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998.
11. Galon J., Franck P., Marincola F.M., Angell H.K., Thurin M., Lugli A., Zlobec I., Berger A., Bifulco C., Botti G., Tatangelo F., Britten C.M., Kreiter S., Chouchane L., Delrio P., Hartmann A., Asslaber M., Maio M., Masucci G.V., Mihm M., Vidal-Vanaclocha F., Allison J.P., Gnjatic S., Hakansson L., Huber C., Singh-Jasuja H., Ottensmeier C., Zwierzina H., Laghi L., Grizzi F., Ohashi P.S., Shaw P.A., Clarke B.A., Wouters B.G., Kawakami Y., Hazama S., Okuno K., Wang E., O'Donnell-Tormey J., Lagorce C., Pawelec G., Nishimura M.I., Hawkins R., Lapointe R., Lundqvist A., Khleif S.N., Ogino S., Gibbs P., Waring P., Sato N., Torigoe T., Itoh K., Patel P.S., Shukla S.N., Palmqvist R., Nagtegaal I.D., Wang Y., D'Arrigo C., Kopetz S., Sinicrope F.A., Trinchieri G., Gajewski T.F., Ascierto P.A. and Fox B.A. (2012). Cancer classification using the immunoscore: A worldwide task force. J. Transl. Med. 10, 205.
12. Gannot G., Richardson A.M., Rodriguez-Canales J., Pinto P.A., Merino M.J., Chuaqui R.F., Gillespie J.W. and Emmert-Buck M.R. (2011). Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer. Am. J. Cancer Res. 1, 120-127.
13. Gulubova M.V., Ananiev J.R., Vlaykova T.I., Yovchev Y., Tsoneva V. and Manolova I.M. (2012). Role of dendritic cells in progression and clinical outcome of colon cancer. Int. J. Colorectal Dis. 27, 159-169.
14. Janikashvili N., Bonnotte B., Katsanis E. and Larmonier N. (2011). The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumorinduced tolerance. Clin. Dev. Immunol. 2011, 430394.
15. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W. and Schellhammer P.F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
16. Kiniwa Y., Miyahara Y., Wang H.Y., Peng W., Peng G., Wheeler T.M., Thompson T.C., Old L.J. and Wang R.F. (2007). CD8+ FoxP3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947-6958.
17. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J. and Schreiber R.D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907.
18. Liu Y., Vlatkovic L., Saeter T., Servoll E., Waaler G., Nesland J.M., Giercksky K.E. and Axcrona K. (2012). Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int. J. Urol. 19, 749-756.
19. Lotan T.L. and Epstein J.I. (2010). Clinical implications of changing definitions within the Gleason grading system. Nat. Rev. Urol. 7, 136-142.
20. Mu L.J., Kyte J.A., Kvalheim G., Aamdal S., Dueland S., Hauser M., Hammerstad H., Waehre H., Raabe N. and Gaudernack G. (2005). Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br. J. Cancer 93, 749-756.
21. Nygren M.K., Tekle C., Ingebrigtsen V.A. and Fodstad O. (2011). B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Front. Biosci. (Elite Ed) 3, 989-993.
22. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C. and Fridman W.H. (2010). Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene 29, 1093-1102.
23. Rabinovich G.A., Gabrilovich D. and Sotomayor E.M. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296.
24. Roth T.J., Sheinin Y., Lohse C.M., Kuntz S.M., Frigola X., Inman B.A., Krambeck A.E., Mckenney M.E., Karnes R.J., Blute M.L., Cheville J.C., Sebo T.J. and Kwon E.D. (2007). B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900.
25. Servoll E., Saeter T., Vlatkovic L., Nesland J., Waaler G. and Beisland H.O. (2010). Does a tertiary gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer? Scand. J. Urol. Nephrol. 44, 217-222.
26. Thompson R.H., Kwon E.D. and Allison J.P. (2009). Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy 1, 129-139.
27. Topalian S.L., Drake C.G. and Pardoll D.M. (2012). Targeting the PD-1/B7-H1(PD-lL) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207-212.
28. Troy A., Davidson P., Atkinson C. and Hart D. (1998). Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160, 214-219.
29. Zang X., Thompson R.H., Al-Ahmadie H.A., Serio A.M., Reuter V.E., Eastham J.A., Scardino P.T., Sharma P. and Allison J.P. (2007). B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. USA 104, 19458-19463.